Do analysts recommend TAK or NVO?

Novo Nordisk A/S has a consensus price target of $64.94, indicating a potential upside of 40.97%. Given Novo Nordisk A/S's higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Novo Nordisk A/S 1 Sell rating(s) 14 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.16

Does the media refer more to TAK or NVO?

In the previous week, Novo Nordisk A/S had 14 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 20 mentions for Novo Nordisk A/S and 6 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.82 beat Novo Nordisk A/S's score of 0.47 indicating that Takeda Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novo Nordisk A/S 10 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PFE or TAK?

Pfizer presently has a consensus price target of $28.28, suggesting a potential upside of 0.52%. Given Pfizer's higher possible upside, analysts plainly believe Pfizer is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pfizer 2 Sell rating(s) 14 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.19 Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media refer more to PFE or TAK?

In the previous week, Pfizer had 76 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 82 mentions for Pfizer and 6 mentions for Takeda Pharmaceutical. Pfizer's average media sentiment score of 1.13 beat Takeda Pharmaceutical's score of 0.82 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 56 Very Positive mention(s) 10 Positive mention(s) 11 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BMY or TAK?

Bristol Myers Squibb currently has a consensus price target of $66.06, indicating a potential downside of 1.59%. Given Bristol Myers Squibb's stronger consensus rating and higher possible upside, research analysts plainly believe Bristol Myers Squibb is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bristol Myers Squibb 1 Sell rating(s) 10 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.56 Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media prefer BMY or TAK?

In the previous week, Bristol Myers Squibb had 69 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 75 mentions for Bristol Myers Squibb and 6 mentions for Takeda Pharmaceutical. Bristol Myers Squibb's average media sentiment score of 1.45 beat Takeda Pharmaceutical's score of 0.82 indicating that Bristol Myers Squibb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bristol Myers Squibb 66 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Takeda Pharmaceutical 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend TAK or SNY?

Sanofi has a consensus target price of $49.50, indicating a potential upside of 10.24%. Given Sanofi's stronger consensus rating and higher possible upside, analysts plainly believe Sanofi is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Sanofi 1 Sell rating(s) 9 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.40

Do analysts rate GSK or TAK?

GSK currently has a consensus price target of $53.00, suggesting a potential upside of 5.44%. Given GSK's higher possible upside, analysts clearly believe GSK is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GSK 2 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.10 Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media favor GSK or TAK?

In the previous week, GSK and GSK both had 6 articles in the media. Takeda Pharmaceutical's average media sentiment score of 0.82 beat GSK's score of 0.32 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Takeda Pharmaceutical 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Takeda Pharmaceutical (TAK) Competitors

$18.08 -0.16 (-0.85%)

As of 12:59 PM Eastern

Compare

TAK vs. NVO, PFE, BMY, SNY, and GSK

Should you buy Takeda Pharmaceutical stock or one of its competitors? Takeda Pharmaceutical's main competitors and comparable companies include Novo Nordisk A/S (NVO), Pfizer (PFE), Bristol Myers Squibb (BMY), Sanofi (SNY), and GSK (GSK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Takeda Pharmaceutical compare to Novo Nordisk A/S?

Takeda Pharmaceutical (NYSE:TAK) and Novo Nordisk A/S (NYSE:NVO) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.7%. Novo Nordisk A/S pays an annual dividend of $0.81 per share and has a dividend yield of 1.8%. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novo Nordisk A/S pays out 19.8% of its earnings in the form of a dividend.

Takeda Pharmaceutical has a beta of -0.08, indicating that its share price is 108% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Novo Nordisk A/S has a net margin of 35.36% compared to Takeda Pharmaceutical's net margin of 3.80%. Novo Nordisk A/S's return on equity of 61.20% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	3.80%	10.95%	5.34%
Novo Nordisk A/S	35.36%	61.20%	21.49%

Novo Nordisk A/S has lower revenue, but higher earnings than Takeda Pharmaceutical. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$4.62T	0.01	-$1.01B	$0.34	53.16
Novo Nordisk A/S	$329.43B	0.62	$15.51B	$4.09	11.26

Novo Nordisk A/S has a consensus price target of $64.94, indicating a potential upside of 40.97%. Given Novo Nordisk A/S's higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Novo Nordisk A/S	1 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.16

In the previous week, Novo Nordisk A/S had 14 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 20 mentions for Novo Nordisk A/S and 6 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.82 beat Novo Nordisk A/S's score of 0.47 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	10 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Novo Nordisk A/S beats Takeda Pharmaceutical on 13 of the 18 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to Pfizer?

Pfizer (NYSE:PFE) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

68.4% of Pfizer shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 0.6% of Pfizer shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Pfizer had 76 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 82 mentions for Pfizer and 6 mentions for Takeda Pharmaceutical. Pfizer's average media sentiment score of 1.13 beat Takeda Pharmaceutical's score of 0.82 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	56 Very Positive mention(s)	10 Positive mention(s)	11 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pfizer has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.08, meaning that its stock price is 108% less volatile than the broader market.

Pfizer has higher earnings, but lower revenue than Takeda Pharmaceutical. Pfizer is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.56	$7.77B	$0.76	37.02
Takeda Pharmaceutical	$4.62T	0.01	-$1.01B	$0.34	53.16

Pfizer presently has a consensus price target of $28.28, suggesting a potential upside of 0.52%. Given Pfizer's higher possible upside, analysts plainly believe Pfizer is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Pfizer has a net margin of 6.80% compared to Takeda Pharmaceutical's net margin of 3.80%. Pfizer's return on equity of 19.63% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	6.80%	19.63%	8.46%
Takeda Pharmaceutical	3.80%	10.95%	5.34%

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.1%. Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.7%. Pfizer pays out 226.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Pfizer beats Takeda Pharmaceutical on 16 of the 20 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to Bristol Myers Squibb?

Bristol Myers Squibb (NYSE:BMY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

Bristol Myers Squibb has a net margin of 18.87% compared to Takeda Pharmaceutical's net margin of 3.80%. Bristol Myers Squibb's return on equity of 66.90% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	18.87%	66.90%	14.74%
Takeda Pharmaceutical	3.80%	10.95%	5.34%

76.4% of Bristol Myers Squibb shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 0.1% of Bristol Myers Squibb shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Bristol Myers Squibb currently has a consensus price target of $66.06, indicating a potential downside of 1.59%. Given Bristol Myers Squibb's stronger consensus rating and higher possible upside, research analysts plainly believe Bristol Myers Squibb is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.56
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Bristol Myers Squibb had 69 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 75 mentions for Bristol Myers Squibb and 6 mentions for Takeda Pharmaceutical. Bristol Myers Squibb's average media sentiment score of 1.45 beat Takeda Pharmaceutical's score of 0.82 indicating that Bristol Myers Squibb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	66 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Takeda Pharmaceutical	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bristol Myers Squibb has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.08, suggesting that its stock price is 108% less volatile than the broader market.

Bristol Myers Squibb has higher earnings, but lower revenue than Takeda Pharmaceutical. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.85	$7.05B	$4.54	14.78
Takeda Pharmaceutical	$4.62T	0.01	-$1.01B	$0.34	53.16

Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 3.8%. Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.7%. Bristol Myers Squibb pays out 55.5% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol Myers Squibb has increased its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Bristol Myers Squibb beats Takeda Pharmaceutical on 18 of the 20 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to Sanofi?

Takeda Pharmaceutical (NYSE:TAK) and Sanofi (NASDAQ:SNY) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

In the previous week, Takeda Pharmaceutical had 5 more articles in the media than Sanofi. MarketBeat recorded 6 mentions for Takeda Pharmaceutical and 1 mentions for Sanofi. Sanofi's average media sentiment score of 1.45 beat Takeda Pharmaceutical's score of 0.82 indicating that Sanofi is being referred to more favorably in the news media.

Company	Overall Sentiment
Takeda Pharmaceutical	Positive
Sanofi	Positive

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Sanofi has lower revenue, but higher earnings than Takeda Pharmaceutical. Sanofi is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$4.62T	0.01	-$1.01B	$0.34	53.16
Sanofi	$48.92B	2.23	$8.84B	$1.91	23.51

Takeda Pharmaceutical has a beta of -0.08, meaning that its stock price is 108% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.7%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 3.9%. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Sanofi is clearly the better dividend stock, given its higher yield and lower payout ratio.

Sanofi has a consensus target price of $49.50, indicating a potential upside of 10.24%. Given Sanofi's stronger consensus rating and higher possible upside, analysts plainly believe Sanofi is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Sanofi	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.40

Sanofi has a net margin of 8.66% compared to Takeda Pharmaceutical's net margin of 3.80%. Sanofi's return on equity of 14.19% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	3.80%	10.95%	5.34%
Sanofi	8.66%	14.19%	7.95%

Summary

Sanofi beats Takeda Pharmaceutical on 16 of the 19 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to GSK?

GSK (NYSE:GSK) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

GSK has higher earnings, but lower revenue than Takeda Pharmaceutical. GSK is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$33.20B	3.06	$7.54B	$3.20	15.71
Takeda Pharmaceutical	$4.62T	0.01	-$1.01B	$0.34	53.16

GSK currently has a consensus price target of $53.00, suggesting a potential upside of 5.44%. Given GSK's higher possible upside, analysts clearly believe GSK is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.10
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

15.7% of GSK shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 10.0% of GSK shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

GSK has a net margin of 14.56% compared to Takeda Pharmaceutical's net margin of 3.80%. GSK's return on equity of 43.23% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
Takeda Pharmaceutical	3.80%	10.95%	5.34%

GSK pays an annual dividend of $1.77 per share and has a dividend yield of 3.5%. Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.7%. GSK pays out 55.3% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, GSK and GSK both had 6 articles in the media. Takeda Pharmaceutical's average media sentiment score of 0.82 beat GSK's score of 0.32 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Takeda Pharmaceutical	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GSK has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.08, indicating that its share price is 108% less volatile than the broader market.

Summary

GSK beats Takeda Pharmaceutical on 13 of the 18 factors compared between the two stocks.

Get Takeda Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TAK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TAK vs. The Competition

Export

Metric	Takeda Pharmaceutical	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$57.90B	$12.20B	$7.23B	$24.21B
Dividend Yield	2.64%	2.61%	2.54%	3.70%
P/E Ratio	53.15	780.46	272.47	30.29
Price / Sales	0.01	793.13	609.96	23.30
Price / Cash	5.91	96.46	79.89	33.34
Price / Book	1.22	12.06	13.10	7.70
Net Income	-$1.01B	$2.81B	$3.46B	$1.07B
7 Day Performance	-0.30%	1.77%	2.09%	0.57%
1 Month Performance	3.57%	5.40%	8.27%	2.24%
1 Year Performance	21.59%	7.04%	26.53%	14.28%

Takeda Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TAK Takeda Pharmaceutical	1.7683 of 5 stars	$18.08 -0.9%	N/A	+22.6%	$57.90B	$4.62T	53.15	47,000
NVO Novo Nordisk A/S	4.1467 of 5 stars	$44.89 -2.2%	$64.94 +44.7%	-14.6%	$204.90B	$46.80B	10.98	69,505	Trending News Analyst Downgrade Gap Down
PFE Pfizer	4.0006 of 5 stars	$26.88 +0.3%	$28.28 +5.2%	+13.5%	$152.69B	$62.58B	35.37	75,000	Positive News
BMY Bristol Myers Squibb	4.7463 of 5 stars	$64.71 +1.4%	$66.06 +2.1%	+43.3%	$130.39B	$48.19B	14.25	32,500	Positive News
SNY Sanofi	3.7041 of 5 stars	$44.41 +1.6%	$49.50 +11.5%	-9.7%	$106.00B	$49.35B	23.25	74,846	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:TAK) was last updated on 8/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Takeda Pharmaceutical (TAK) Competitors

TAK vs. NVO, PFE, BMY, SNY, and GSK

How does Takeda Pharmaceutical compare to Novo Nordisk A/S?

Summary

How does Takeda Pharmaceutical compare to Pfizer?

Summary

How does Takeda Pharmaceutical compare to Bristol Myers Squibb?

Summary

How does Takeda Pharmaceutical compare to Sanofi?

Summary

How does Takeda Pharmaceutical compare to GSK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAK vs. The Competition

Takeda Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Takeda Pharmaceutical (TAK) Competitors

TAK vs. NVO, PFE, BMY, SNY, and GSK

How does Takeda Pharmaceutical compare to Novo Nordisk A/S?

Is TAK or NVO a better dividend stock?

Which has more volatility & risk, TAK or NVO?

Do insiders and institutionals hold more shares of TAK or NVO?

Is TAK or NVO more profitable?

Which has stronger valuation & earnings, TAK or NVO?

Do analysts recommend TAK or NVO?

Does the media refer more to TAK or NVO?

Summary

How does Takeda Pharmaceutical compare to Pfizer?

Do institutionals & insiders have more ownership in PFE or TAK?

Does the media refer more to PFE or TAK?

Which has more risk and volatility, PFE or TAK?

Which has stronger earnings & valuation, PFE or TAK?

Do analysts rate PFE or TAK?

Is PFE or TAK more profitable?

Is PFE or TAK a better dividend stock?

Summary

How does Takeda Pharmaceutical compare to Bristol Myers Squibb?

Is BMY or TAK more profitable?

Do insiders & institutionals believe in BMY or TAK?

Do analysts recommend BMY or TAK?

Does the media prefer BMY or TAK?

Which has more risk & volatility, BMY or TAK?

Which has higher valuation and earnings, BMY or TAK?

Is BMY or TAK a better dividend stock?

Summary

How does Takeda Pharmaceutical compare to Sanofi?

Does the media favor TAK or SNY?

Do institutionals & insiders believe in TAK or SNY?

Which has preferable earnings & valuation, TAK or SNY?

Which has more risk and volatility, TAK or SNY?

Is TAK or SNY a better dividend stock?

Do analysts recommend TAK or SNY?

Is TAK or SNY more profitable?

Summary

How does Takeda Pharmaceutical compare to GSK?

Which has higher earnings & valuation, GSK or TAK?

Do analysts rate GSK or TAK?

Do insiders and institutionals have more ownership in GSK or TAK?

Is GSK or TAK more profitable?

Is GSK or TAK a better dividend stock?

Does the media favor GSK or TAK?

Which has more volatility & risk, GSK or TAK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAK vs. The Competition

Takeda Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools